Yes and actual compelling data from a blinded trial hitting P values will move the needle. We shouldn’t have reported on the 350 mg open label. The market only cares about real results.


So I believe if the 700 mg NASH results are good we could see a increase in the SP which we need if we are going to start to sell the 200 million shares soon to keep us afloat.